Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PALO ALTO, Calif., June 8, 2022 /PRNewswire/ --Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom. Oral presentation: Title: Lonafarnib Combination with Peginterferon Lambda Diminished Triphasic HDV Kinetic Pattern Poster presentations: Title: Strong Correlation Between HBsAg, ALT and HDV-RNA Levels in Patients with Chronic Hepatitis Title: Clinical Features Predictive of Cirrhosis in a Large Cohort of Patients with Chronic Hepatitis Delta Infection - Insights from the D-LIVR Trial Title: Mathematical Modeling of HDV RNA Kinetics Suggests High Peginterferon Lambda Efficacies in Blocking Viral Production and Infection: Insights from the LIMT-1 Study Additional Congress Activities: Event: 21st Hepatitis Delta International Network Event: Eiger Booth #101 Event: Eiger Reception for Investigators, Investors and Analysts About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from TOGETHER, a Phase 3 investigator-initiated study. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. Contacts
Investors: Media:
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-multiple-presentations-at-the-european-association-for-the-study-of-the-liver-easl-international-liver-congress-2022-301563811.html SOURCE Eiger BioPharmaceuticals, Inc. |
||
Company Codes: NASDAQ-NMS:EIGR |